Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Recipient : Portage Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Portage Biotech Provides Research and Development Update
Details : TT-10, an oral small molecule drug targeting the Adenosine A2A receptor (A2AR) in patients with advanced solid tumors both as a monotherapy and in combination with other anti-cancer agents.
Brand Name : TT-10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
September 14, 2022
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Recipient : Portage Biotech
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : PORT-6
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Portage Biotech
Deal Size : $53.0 million
Deal Type : Acquisition
Details : As a result of the transaction, Portage acquires four best-in-class assets including TT-10/PORT-6, targeting different aspects of the adenosine pathway, and is now in a unique position to evaluate the role of adenosine in cancer and other diseases.
Brand Name : TT-10
Molecule Type : Small molecule
Upfront Cash : $21.0 million
July 06, 2022
Lead Product(s) : PORT-6
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Portage Biotech
Deal Size : $53.0 million
Deal Type : Acquisition
Lead Product(s) : TT-4
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : TT-4, an oral small molecule drug targeting the Adenosine A2B receptor (A2BR). Tarus plans to initiate a Phase 1a/1b study in the third quarter of 2021 to evaluate TT-4 in patients with advanced solid tumors both as a monotherapy and in combination.
Brand Name : TT-4
Molecule Type : Small molecule
Upfront Cash : Not Applicable
May 27, 2021
Lead Product(s) : TT-4
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TT-4
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tarus Therapeutics Seeks To Initiate Clinical Trial of TT-4 (A2BR Antagonist) in Cancer Patients
Details : The application includes extensive preclinical data on TT-4's biological activity and safety profile, as well as details on how the therapy would be manufactured and administered to trial participants.
Brand Name : TT-4
Molecule Type : Small molecule
Upfront Cash : Not Applicable
April 28, 2021
Lead Product(s) : TT-4
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Tarus Therapeutics Seeks to Initiate Clinical Trial of TT-10 (A2AR antagonist) in Cancer Patients
Details : The application includes extensive preclinical data on TT-10's biological activity and safety profile, as well as details on how the therapy would be manufactured and administered to trial participants.
Brand Name : TT-10
Molecule Type : Small molecule
Upfront Cash : Not Applicable
March 10, 2021
Lead Product(s) : TT-10
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?